Skip to main content

ABVC BioPharma, Inc. (ABVC)

NASDAQ: ABVC · IEX Real-Time Price · USD
2.47 -0.02 (-0.60%)
Sep 21, 2021 3:37 PM EDT - Market open
Market Cap70.71M
Revenue (ttm)472,337
Net Income (ttm)n/a
Shares Out26.68M
EPS (ttm)-0.45
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume127,594
Open2.50
Previous Close2.48
Day's Range2.45 - 2.59
52-Week Range1.95 - 4.75
Beta0.17
Analystsn/a
Price Target9.50 (+285.4%)
Est. Earnings Daten/a

About ABVC

American BriVision (Holding) Corporation, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, a combination therapy for triple negative breast cancer; ABV-1504 for major depressive disorders; ABV-1505 for attention deficit hyperactivity disorder; ABV-1703 for the treatment of pancreatic cancer; ABV-1702 to treat myelodysplastic syndromes; ABV-1601 for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment ...

IndustryBiotechnology
IPO DateAug 3, 2021
Employees30
Stock ExchangeNASDAQ
Ticker SymbolABVC
Full Company Profile

Financial Performance

In 2020, ABVC BioPharma's revenue was $483,045, a decrease of -31.16% compared to the previous year's $701,719. Losses were -$9.79 million, 168.9% more than in 2019.

Financial Statements

News

Why ABVC BioPharma Shares Are Trading Higher Today

ABVC BioPharma Inc (NASDAQ: ABVC) is trading higher Wednesday after the company announced new PCT filings for major depressive disorder (MDD) and attention-deficit hyperactivity disorder (ADHD) treatmen...

2 weeks ago - Benzinga

ABVC BioPharma Announces New PCT Filings for MDD and ADHD Treatments

FREMONT, CA, Sept. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology...

2 weeks ago - GlobeNewsWire

ABVC BioPharma Report Updated by Zacks/SCR

FREMONT, CA, Aug. 30, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology,...

3 weeks ago - GlobeNewsWire

ABVC BioPharma Provides Vitargus® Update

FREMONT, CA, Aug. 26, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology,...

3 weeks ago - GlobeNewsWire

ABVC BioPharma Reports Second Quarter 2021 Results

Clinical Trials Continue Despite COVID-19 Restrictions

1 month ago - GlobeNewsWire

WallachBeth Capital Announces the Completion of an Underwritten Public Offering of 1,100,000 Units for ABVC BioPharma...

JERSEY CITY, N.J., Aug. 6, 2021 /PRNewswire/ -- WallachBeth Capital, a leading provider of capital markets and institutional execution services, announced the completion of an underwritten public offeri...

1 month ago - PRNewsWire

ABVC BioPharma, Inc. Announces Pricing of $6.875 Million Firm Commitment Offering

FREMONT, CA, Aug. 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, centra...

1 month ago - GlobeNewsWire

American BriVision Issues Shareholder Letter Outlining Achievements of 2020 and Outlook for 2021

via NewMediaWire  -- American BriVision (Holding) Corporation (OTCQB: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, central nervous system (C...

8 months ago - GlobeNewsWire